Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 24673735)

1.

Preparing for tomorrow: molecular diagnostics and the changing nonsmall cell lung cancer landscape.

Boyer M, Tsao MS, Jänne P, Ramalingam S, Pitman Lowenthal S, Alam M.

Asia Pac J Clin Oncol. 2014 Apr;10 Suppl 2:2-10. doi: 10.1111/ajco.12189. Review.

PMID:
24673735
2.

How and when to use genetic markers for nonsmall cell lung cancer.

Lazarus DR, Ost DE.

Curr Opin Pulm Med. 2013 Jul;19(4):331-9. doi: 10.1097/MCP.0b013e328362075c. Review.

3.

National Working Group Meeting on ALK diagnostics in lung cancer.

Cooper W, Fox S, O'Toole S, Morey A, Frances G, Pavlakis N, O'Byrne K, Dettrick A, Leong T, Rathi V, Spagnolo D, Hemmings C, Singh M, Moffat D, Tsao MS, Wilner K, Buller R, Pitman Lowenthal S, Arifeen S, Binko J, Alam M.

Asia Pac J Clin Oncol. 2014 Apr;10 Suppl 2:11-7. doi: 10.1111/ajco.12190.

PMID:
24673736
4.

[A new target in non-small cell lung cancer: EML4-ALK fusion gene].

Wang H, Yuan J, Ma Z.

Zhongguo Fei Ai Za Zhi. 2011 Jun;14(6):538-42. doi: 10.3779/j.issn.1009-3419.2011.06.11. Review. Chinese.

5.

Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.

Proietti A, Alì G, Pelliccioni S, Lupi C, Sensi E, Boldrini L, Servadio A, Chella A, Ribechini A, Cappuzzo F, Miccoli M, Fontanini G.

Cancer Cytopathol. 2014 Jun;122(6):445-53. doi: 10.1002/cncy.21418. Epub 2014 Mar 19.

PMID:
24648382
6.

Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication.

Rafael OC, Aziz M, Raftopoulos H, Vele OE, Xu W, Sugrue C.

Cancer Cytopathol. 2014 Jun;122(6):454-8. doi: 10.1002/cncy.21426. Epub 2014 Apr 10.

PMID:
24723383
7.

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E, Mino N, Iwakiri S, Sato K, Miyahara R, Okubo K, Manabe T, Date H.

Ann Surg Oncol. 2010 Mar;17(3):889-97. doi: 10.1245/s10434-009-0808-7.

PMID:
20183914
8.

Genes and pathology of non-small cell lung carcinoma.

Sakashita S, Sakashita M, Sound Tsao M.

Semin Oncol. 2014 Feb;41(1):28-39. doi: 10.1053/j.seminoncol.2013.12.008. Epub 2013 Dec 12. Review.

PMID:
24565579
9.

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M; University of Hong Kong Lung Cancer Study Group.

Cancer. 2009 Apr 15;115(8):1723-33. doi: 10.1002/cncr.24181.

10.

[Research progress in non-small cell lung cancer with concomitant EML4-ALK fusion gene and EGFR gene mutation].

Zeng Z, Wu Y.

Zhongguo Fei Ai Za Zhi. 2011 Nov;14(11):880-4. doi: 10.3779/j.issn.1009-3419.2011.11.09. Review. Chinese.

11.

ALK inhibitors in the treatment of advanced NSCLC.

Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.

Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7. Review.

PMID:
23931927
12.

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation.

Miyanaga A, Shimizu K, Noro R, Seike M, Kitamura K, Kosaihira S, Minegishi Y, Shukuya T, Yoshimura A, Kawamoto M, Tsuchiya S, Hagiwara K, Soda M, Takeuchi K, Yamamoto N, Mano H, Ishikawa Y, Gemma A.

BMC Cancer. 2013 May 29;13:262. doi: 10.1186/1471-2407-13-262.

13.

PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.

Pilotto S, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E.

Expert Opin Pharmacother. 2013 Apr;14(5):597-608. doi: 10.1517/14656566.2013.778828. Epub 2013 Mar 9. Review.

PMID:
23472711
14.

What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements.

Cooper WA, O'toole S, Boyer M, Horvath L, Mahar A.

Pathology. 2011 Feb;43(2):103-15. doi: 10.1097/PAT.0b013e328342629d. Review.

PMID:
21233671
15.

Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.

Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, Kim SH, Ha SJ, Kim SK, Chung KY, Soo R, Kim JH, Cho BC.

Cancer. 2012 Feb 1;118(3):729-39. doi: 10.1002/cncr.26311. Epub 2011 Jun 30.

16.

The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.

Kelleher FC, McDermott R.

Eur J Cancer. 2010 Sep;46(13):2357-68. doi: 10.1016/j.ejca.2010.04.006. Epub 2010 May 5. Review.

PMID:
20451371
17.
18.

Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations.

Dacic S.

J Clin Pathol. 2013 Oct;66(10):870-4. doi: 10.1136/jclinpath-2012-201336. Epub 2013 Jun 25. Review.

PMID:
23801495
19.

Should we continue to use the term non-small-cell lung cancer?

Gazdar AF.

Ann Oncol. 2010 Oct;21 Suppl 7:vii225-9. doi: 10.1093/annonc/mdq372. Review.

20.

[Molecular pathological diagnosis in cytopathology of non-small-cell lung cancer. Standardization of specimen processing].

Warth A, Bubendorf L, Gütz S, Morresi-Hauf A, Hummel M, Junker K, Lehmann U, Petersen I, Schnabel PA.

Pathologe. 2013 Jul;34(4):310-7. doi: 10.1007/s00292-013-1764-3. Review. German.

PMID:
23728235
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk